Gilles Brisson

Part of Sanofi, Sanofi-Aventis Europe SAS is a pharmaceutical company based in Paris, France. The French company manufactures pharmaceuticals. The CEO of the private company is Jérôme Contamine.

Ethypharm SAS is a holding company, which engages in developing pharmaceutical products. It offers treatment for pain and addiction, as well as complex generic drugs. The company was founded by G?rard Leduc and Patrice Debregreas in 1977 and is headquartered in Saint-Cloud, France.

Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products.

Founded in 1982, Aventis Pharma SARL is a French pharmaceutical company that manufactures pharmaceuticals. Part of Sanofi, the private company is based in Antony, France.

Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France.

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development